Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06595017
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-10
Brief Title:
Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluation of the Effect of Magnesium Sulfate Injection in Comparison to Lidocaine for Management of Myofascial Pain Dysfunction Syndrome a Randomized Controlled Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to investigate the effectiveness of Magnesium Sulphate in the management of myofascial pain dysfunction syndrome in comparison to Lidocaine and Saline
A total of 75 patients suffering from myofascial pain dysfunction syndrome will be assigned into one of three groups each with 25 patients
Group A Saline includes patients enrolled for Saline injection into the trigger points Group B Magnesium Sulphate includes patients enrolled for Magnesium Sulphate injection into the trigger points Group C Lidocaine includes patients who will be enrolled for Lidocaine injection into the trigger points The primary outcome that will be investigated is pain with a visual analogue score and secondary outcomes will be maximum mouth opening between edges of upper and lower incisors with millimeters electrical activity with Electromyography and quality of life assessed using the Oral Health Impact Profile questionnaire The outcomes will be assessed pre-injection 1month after injection 3months after injection and 6 months after injection
A total of 75 patients suffering from myofascial pain dysfunction syndrome will be assigned into one of three groups each with 25 patients
Group A Saline includes patients enrolled for Saline injection into the trigger points Group B Magnesium Sulphate includes patients enrolled for Magnesium Sulphate injection into the trigger points Group C Lidocaine includes patients who will be enrolled for Lidocaine injection into the trigger points The primary outcome that will be investigated is pain with a visual analogue score and secondary outcomes will be maximum mouth opening between edges of upper and lower incisors with millimeters electrical activity with Electromyography and quality of life assessed using the Oral Health Impact Profile questionnaire The outcomes will be assessed pre-injection 1month after injection 3months after injection and 6 months after injection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None